Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05401097
Title Ivosidenib or Enasidenib Followed by Azacitidine Plus Venetoclax or Azacitidine Plus Venetoclax Followed by Ivosidenib or Enasidenib for the Treatment of IDH Mutated Acute Myeloid Leukemia in Older Patients. The I-DATA Study
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Alice Mims
Indications

acute myeloid leukemia

Therapies

Ivosidenib

Azacitidine + Enasidenib + Venetoclax

Azacitidine + Ivosidenib + Venetoclax

Enasidenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST